Claims for Patent: 7,875,283

Summary for Patent: 7,875,283

Title:	Biodegradable polymers for use with implantable medical devices
Abstract:	The present invention relates to a stent fabricated of or coated with a composition comprising a biodegradable hydrophobic polymer containing water-labile bonds such that a device fabricated of the composition or the surface of a device coated with the requisite mechanical characteristics required of a stent and the polymer erodes from its outer surface inward.
Inventor(s):	Hossainy; Syed F. A. (Fremont, CA), Dutta; Debashis (Santa Clara, CA)
Assignee:	Advanced Cardiovascular Systems, Inc. (Santa Clara, CA)
Application Number:	11/155,036
Patent Claims:	1. A stent fabricated from or coated with a composition comprising a bioerodible hydrophobic polymer having a plurality of water-labile bonds wherein the polymer has sufficient mechanical strength to withstand forces present in mammalian vascular systems and also bioerodes from its surface inward. 2. The stent of claim 1, wherein the water-labile bonds comprise one or more bond type(s) independently selected from the group consisting of ester bonds, orthoester bonds, anhydride bonds, imide bonds and combinations thereof. 3. The stent of claim 2, wherein the water labile bonds comprise a constitutional unit derived from trimellitylimido-L-tyrosine. 4. The stent of claim 3, wherein the constitutional unit derived from trimellitylimido-L-tyrosine comprises from about 20 to about 40 wt % of the hydrophobic polymer. 5. The stent of claim 2, wherein the water labile bonds comprise one or more constitutional unit(s) derived from a compound or compounds independently selected from the group consisting of sebacic acid, di-ortho-carboxyphenyl sebacate, salicylic acid, maleic acid, 1,3-bis-para-carboxyphenoxypropane, 1,6-bis-para-carboxyphenoxy-hexane, trimellitylimido-L-tyrosine, terephthalic acid, L-lactic acid, D-lactic acid, DL-lactic acid, L-aspartic acid and 4-hydroxy-L-proline. 6. The stent of claim 5, wherein the water-labile bonds further comprise one or more constitutional unit(s) derived from a compound or compounds selected from the group consisting of 1,10-decanediol, ethylene glycol, and 1,2,6-hexanetriol. 7. The stent of claim 6, wherein the water-labile bond(s) further comprise one or more constitutional unit(s) derived from a compound or compounds selected from the group consisting of tri(1C-12C)alkyl ortho(1C-12C)carboxylates. 8. The stent of claim 2, wherein the water-labile bond(s) comprise one or more constitutional unit(s) derived from a compound or compounds selected from the group consisting of tri(1 C-12C)alkyl ortho(1 C-12C)carboxylates. 9. The stent of claim 1, wherein the hydrophobic polymer comprises constitutional units derived from trimellitylimido-L-tyrosine, sebacic acid and 1,3-bis(para-carboxyphenoxy)propane. 10. The stent of claim 1, wherein the hydrophobic polymer comprises constitutional units derived from 1,6-bis(para-carboxyphenoxy)hexane and di-ortho-carboxyphenoxysebacate acetic anhydride. 11. The stent of claim 1, wherein the hydrophobic polymer comprises constitutional units derived from maleic acid and sebacic acid. 12. The stent of claim 1, wherein the hydrophobic polymer comprises constitutional units derived from 1,3-bis(para-carboxyphenoxy)propane, sebacic acid and salicylic acid. 13. The stent of claim 1, wherein the hydrophobic polymer comprises constitutional units derived from 1,2,6-hexanetriol and trimethylorthoacetate. 14. The stent of claim 1, wherein the hydrophobic polymer comprises constitutional units derived from poly(ethylene glycol) and poly(butylene terephthalate). 15. The stent of claim 1, further comprising one or more therapeutic substance(s). 16. The stent of claim 15, wherein the therapeutic substance(s) is(are) selected from the group consisting of actinomycin D, paclitaxel, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride, mitomycin, sodium heparin, low molecular weight heparins, heparinoids, heparin derivatives having hydrophobic counter ions, hirudin, argatroban, forskolin, vapiprost, prostacyclin, dextran, D-phe-pro-arg-chloromethylketone, dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin, angiopeptin, captopril, cilazapril, lisinopril, nifedipine, colchicine, fibroblast growth factor (FGF) antagonists, fish oil (.omega.-3- fatty acid), histamine antagonists, lovastatin, monoclonal antibodies, nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine, nitric oxide, permirolast potassium, alpha-interferon, genetically engineered epithelial cells, rapamycin, everolimus and dexamethasone. 17. The stent of claim 1, wherein the biodegradable hydrophobic polymer further comprises one or more constitutional unit(s) derived from one or more therapeutic substance(s). 18. The stent of claim 17, wherein the therapeutic substance(s) is(are) selected from the group consisting of salicylic acid, nitric oxide, poly(ethylene glycol), heparin, low molecular weight heparin, hepariniods and hyaluronic acid. 19. The stent of claim 1, wherein the biodegradable hydrophobic polymer comprises a block copolymer of polyethylene glycol and poly(butylene terephthalate). 20. The stent of claim 1, further comprising an alternative polymer.

Details for Patent 7,875,283

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2040-01-28